Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Enasidenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 3Idhifa

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Idhifa

    Enasidenib

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Idhifa

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Celgene

    Enasidenib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 20

    2016 Revenue in Millions : 0

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Idhifa

    Enasidenib

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Idhifa

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Celgene

    Enasidenib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 72

    2017 Revenue in Millions : 20

    Growth (%) : 260%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Idhifa

    Enasidenib

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Idhifa

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb/Celgene

    Enasidenib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 77

    2018 Revenue in Millions : 50

    Growth (%) : 54

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF